<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The introduction of monoclonal antibodies into the treatment protocols for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>(mCRC)has significantly improved outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>There are some patients with mCRC, initially judged unresectable, who become resectable after chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>For patients with isolated <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e>, surgical resection is recommended when feasible </plain></SENT>
<SENT sid="3" pm="."><plain>We experienced a case in which an initially unresectable mCRC <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> converted into a resectable one after cetuximab monotherapy as third-line treatment </plain></SENT>
<SENT sid="4" pm="."><plain>The sample from hepatectomy was a pathologically complete response; no remnants were detected </plain></SENT>
<SENT sid="5" pm="."><plain>The management of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> contributes to improvements in the clinical setting </plain></SENT>
<SENT sid="6" pm="."><plain>For conducting a multimodal treatment of mCRC, the participation of various specialists such as medical oncologists, colorectal/hepaticsurgeons and diagnostic/therapeutic radiologists is indispensable </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, it is necessary to construct an evidence-based consensus on potentially resectable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> in each hospital </plain></SENT>
</text></document>